news
Targeting TYK2 with Deucravacitinib: Pharmacodynamic Insights from the Phase 2 PAISLEY Trial in Systemic Lupus Erythematosus
Deucravacitinib, an oral selective TYK2 inhibitor, demonstrates significant suppression of interferon and B-cell pathway biomarkers in active SLE patients, supporting ongoing phase 3 trials for this challenging autoimmune disease.
